# Dermatitis Herpetiformis

Confirm suspected dermatitis herpetiformis with direct immunofluorescence of uninvolved perilesional skin, then treat the underlying gluten-sensitive enteropathy with a lifelong gluten-free diet while using dapsone for rapid control when pruritus or lesions remain active.

**Clinical question:** How should physicians confirm dermatitis herpetiformis and integrate gluten-free diet, dapsone, and celiac disease follow-up?

Updated: 2026-09-15T23:17:39.821391+00:00

## What matters in practice
- For suspected dermatitis herpetiformis, obtain direct immunofluorescence from normal-appearing perilesional skin; granular IgA at dermal papillae or along the dermal-epidermal junction confirms the diagnosis. [21][24]
- A lifelong strict gluten-free diet is definitive therapy because dapsone relieves itch and skin disease but does not treat small-intestinal inflammation. [1][7]
- Use oral dapsone when rapid lesion and pruritus control is needed during early dietary treatment, but monitor for hemolytic anemia and methemoglobinemia. [1][12][14]
- Check celiac-specific serology and evaluate nutritional and autoimmune consequences of gluten-sensitive enteropathy; negative serology does not exclude dermatitis herpetiformis. [1][4][17]
- A proven dermatitis herpetiformis diagnosis can establish celiac disease without routine duodenal biopsy; reserve further intestinal evaluation for clinically equivocal circumstances. [24]

## Confirm dermatitis herpetiformis with perilesional direct immunofluorescence

Do not base the diagnosis on morphology, routine histology, or celiac serology alone.

In a patient with a symmetric, intensely pruritic papulovesicular or excoriated eruption on the elbows, knees, buttocks, scalp, or other extensor surfaces, obtain a biopsy of normal-appearing skin immediately adjacent to an active lesion for direct immunofluorescence (DIF). Granular IgA deposits in the papillary dermis, at papillary tips, or along the dermal-epidermal junction are diagnostic of dermatitis herpetiformis (DH). Perilesional uninvolved skin is the preferred specimen because lesional tissue may not retain the diagnostic IgA pattern. [5][21][22][24]

Routine histopathology can support the clinical impression when it shows a subepidermal blister with neutrophilic microabscesses in dermal papillae, but it does not replace DIF. A histologically compatible biopsy without granular IgA should prompt reconsideration of other immunobullous disorders rather than empiric labeling as DH. [12][24]

DIF is reported to have sensitivity and specificity close to 100% when performed from uninvolved perilesional skin. A positive DIF establishes DH even when serum celiac antibodies are absent, because some patients with DH lack circulating celiac-specific antibodies. [4][24]
- Biopsy target: uninvolved, normal-appearing skin adjacent to the eruption for DIF. [21][22][24]
- Diagnostic pattern: granular IgA in dermal papillae, along the basement membrane, or both with papillary accentuation. [21][24]
- Do not use a negative tissue transglutaminase or endomysial antibody result to exclude DH. [1][4][17]

*Tests that change the diagnostic pathway in suspected dermatitis herpetiformis. [1][21][24]*

| Test | Actionable result | What the result changes |
| --- | --- | --- |
| Perilesional skin DIF | Granular IgA in papillary dermis or along dermal-epidermal junction [21][24] | Confirms DH and supports celiac disease diagnosis without routine duodenal biopsy. [24] |
| Routine skin histopathology | Subepidermal blister with neutrophilic papillary microabscesses [12] | Supports DH but requires DIF confirmation. [24] |
| Serum IgA tissue transglutaminase and endomysial antibody | Positive celiac-specific autoantibodies [1] | Supports associated gluten-sensitive enteropathy; negative serology does not rule out DH. [1][4][17] |
| IgG tissue transglutaminase in IgA deficiency | Positive IgG tTG result [22] | Provides celiac-directed serologic assessment when IgA testing is unreliable. [22] |

## Treat confirmed DH as gluten-sensitive enteropathy

Cutaneous disease may be the dominant presentation despite limited gastrointestinal symptoms.

DH is the specific cutaneous manifestation of celiac disease/gluten-sensitive enteropathy. Most, but not all, affected patients have circulating anti-tTG antibodies and duodenal villous atrophy; approximately 70% have villous atrophy, while others have celiac-like inflammatory intestinal changes. Therefore, absence of diarrhea, weight loss, or malabsorption symptoms should not alter the need for a lifelong gluten-free diet after diagnostic confirmation. [1][17][22]

For a patient with biopsy-proven DH, a duodenal biopsy is generally unnecessary to diagnose celiac disease. Consider gastrointestinal evaluation when the diagnosis remains equivocal, when DIF is unavailable or nondiagnostic, or when another cause of villous atrophy is being considered. In equivocal villous atrophy with negative celiac serology, HLA-DQ2/DQ8 testing can help: negative HLA typing excludes seronegative celiac disease, whereas positive typing is not diagnostic because these haplotypes occur in 30% to 40% of Caucasian populations. [4][24]

Assess enteropathy-related consequences at baseline and during follow-up with complete blood count, ferritin, folate, vitamin B12, calcium, alkaline phosphatase, aminotransferases, thyroid-stimulating hormone with thyroid hormone testing, and serum glucose. Anti-TG2, endomysial antibody, or deamidated gliadin peptide testing can support assessment of dietary adherence, but serology cannot substitute for a structured dietary interview. [5]
- Order celiac serology while the patient is consuming gluten when feasible; use IgG tTG rather than IgA tTG in IgA deficiency. [22]
- If unexplained villous atrophy and negative celiac serology create diagnostic uncertainty, obtain HLA-DQ2/DQ8 testing before assigning seronegative celiac disease. [4]
- Review medications that can cause enteropathy, including olmesartan, azathioprine, mycophenolate mofetil, methotrexate, and chemotherapy, when intestinal findings are atypical. [4]

*Celiac-directed evaluation after dermatitis herpetiformis is confirmed. [4][5][22][24]*

| Clinical situation | Next action | Interpretation |
| --- | --- | --- |
| Positive perilesional DIF for granular IgA | Start celiac-directed management; duodenal biopsy is not routinely required. [24] | Biopsy-proven DH establishes the celiac disease association. [24] |
| DH suspected but serum celiac antibodies negative | Proceed with perilesional DIF; do not exclude DH from serology alone. [1][4][17] | Patients with DH may lack specific circulating antibodies. [4] |
| Villous atrophy with negative celiac serology | Obtain HLA-DQ2/DQ8 testing and review alternative enteropathy causes. [4] | Negative HLA typing excludes seronegative celiac disease. [4] |
| Stable treated disease | At least annual review of absorption, autoimmune conditions, liver tests, dietary adherence, and treatment adverse effects. [5] | Serology complements but does not replace dietary assessment. [5] |

## Prescribe a lifelong strict gluten-free diet

Dietary treatment addresses both the rash and the underlying enteropathy.

Prescribe a lifelong strict gluten-free diet (GFD) for every patient with confirmed DH and arrange dietary counseling at initiation. The GFD is the treatment of choice because it treats the gluten-driven enteropathy and, over time, reduces skin disease and medication dependence. In a 212-patient experience, 78 of 133 patients who followed the diet achieved complete rash clearance with diet alone, and many remaining adherent patients reduced medication requirements. [1][3]

Set expectations that cutaneous control may remain incomplete during the first months of a GFD. Dapsone is appropriate as bridging therapy for active pruritus and lesions during this interval, whereas dietary nonadherence is a likely contributor to recurrent activity. Patients who lapse more than once weekly were classified as effectively following a normal diet in the long-term cohort. [1][3]

Review medications, supplements, and dietary products for gluten exposure when rash activity persists despite reported adherence. Dapsone should not be presented as an alternative to dietary treatment: it improves itch but has no effect on small-intestinal inflammation. [7][16]
- Initiate dietitian-supported gluten avoidance at the time DH is confirmed. [1]
- Use clinical skin activity, structured dietary history, and celiac serology as complementary—not interchangeable—measures of adherence. [5]
- Continue surveillance for nutritional deficits, autoimmune disease, liver abnormalities, and drug adverse effects after rash suppression. [5]

*Roles of dietary and symptomatic therapy in dermatitis herpetiformis. [1][3][7][12]*

| Intervention | Primary role | Key limitation or tradeoff |
| --- | --- | --- |
| Lifelong strict gluten-free diet | Definitive treatment for DH and associated gluten-sensitive enteropathy. [1] | Skin improvement may take months; requires ongoing dietary counseling and adherence assessment. [1][3] |
| Oral dapsone | Rapid control of pruritus and cutaneous lesions when disease remains active early in dietary treatment. [1][12] | Does not treat intestinal inflammation; can cause hemolytic anemia and methemoglobinemia. [7][12][14] |
| Ultrapotent topical corticosteroid | Adjunct for skin lesion control with dapsone and GFD. [1] | Does not replace systemic dietary treatment. [1] |

## Use dapsone for rapid control, with hematologic vigilance

Select dapsone for active disease requiring faster relief than diet alone provides.

Use oral dapsone when severe pruritus or ongoing skin lesions require rapid suppression while a strict GFD takes effect. Dapsone is described as the most effective drug for controlling DH skin lesions and pruritus during the first months after dietary initiation; a usual starting dose of 100 mg/day is reported. Do not escalate beyond source-supported dosing on the basis of this reference alone. [1][12]

Before and during dapsone treatment, obtain blood testing sufficient to detect hematologic toxicity and actively evaluate symptoms compatible with hemolysis or methemoglobinemia. Dapsone-associated hemolytic anemia, methemoglobinemia, leukopenia, and hypersensitivity syndrome are clinically important toxicities; patients with low G6PD activity are particularly vulnerable to hemolysis and methemoglobinemia. [12][14]

If cyanosis, dizziness, nausea, vomiting, unexplained low pulse oximetry, or dark-brown blood develops after dapsone exposure, stop dapsone and evaluate urgently for methemoglobinemia and hemolysis. Methylene blue may aggravate hemolysis in G6PD deficiency; management therefore requires confirmation of the patient’s G6PD status and toxicology-informed treatment selection. [14]
- Consider ultrapotent topical corticosteroids as adjunctive therapy with dapsone and GFD, not as stand-alone management of confirmed DH. [1]
- For localized disease, topical dapsone 5% cream twice daily has been reported with excellent response in two pediatric cases; this is limited case-based evidence rather than established standard systemic therapy. [9]
- At follow-up, reassess skin control, GFD adherence, dapsone adverse effects, and celiac-associated complications. [1][5]

*Dapsone safety actions for dermatitis herpetiformis. [12][14]*

| Finding or circumstance | Immediate action | Clinical concern |
| --- | --- | --- |
| Initiating oral dapsone | Obtain baseline blood testing and assess G6PD activity before or at treatment initiation. [12][14] | Hemolytic anemia and methemoglobinemia; low G6PD increases risk. [14] |
| Cyanosis, dizziness, nausea, vomiting, or brown blood after exposure | Stop dapsone and urgently evaluate for methemoglobinemia and hemolysis. [14] | Dapsone-induced methemoglobinemia may coexist with hemolytic anemia. [14] |
| Evidence of anemia or leukopenia during therapy | Reassess dapsone exposure and obtain repeat blood testing. [12] | Dapsone can cause anemia and leukopenia. [12] |
| Persistently active rash during early GFD | Verify gluten avoidance and use dapsone when rapid cutaneous control is required. [1][3] | Dietary response may be delayed by months. [1] |

## Follow disease activity, dietary adherence, and enteropathy complications

Rash suppression alone is not an adequate endpoint.

Schedule follow-up during the initial treatment period to document lesion and pruritus response, review the GFD with a structured dietary history, and monitor dapsone adverse effects. Once disease is stable and the patient can manage the diet, transition to annual follow-up. [1][5]

At annual review, assess full blood count, ferritin, serum folate, vitamin B12, calcium, alkaline phosphatase, aminotransferases, thyroid status, and serum glucose. Use celiac antibody testing as an adjunct to—not a substitute for—dietary assessment. Persistent rash should trigger an adherence review and reconsideration of diagnostic accuracy if the original DIF was not definitive. [5]

Escalate diagnostic evaluation when the clinical phenotype is atypical, DIF is negative or unavailable, or findings suggest a competing immunobullous disease. In patients with equivocal intestinal pathology and negative celiac serology, a diagnostic gluten challenge has been suggested at at least 10 g gluten daily for 6 to 8 weeks, although dose and duration are not standardized; this approach is for resolving uncertainty, not routine monitoring of established DH. [4]
- Annual stable-disease surveillance: CBC, ferritin, folate, vitamin B12, calcium, alkaline phosphatase, AST/ALT, thyroid testing, and serum glucose. [5]
- Reassess medication and supplement exposures when serology, symptoms, or nutritional measures suggest ongoing gluten exposure. [4][5]
- Do not use dapsone response as proof of DH; confirmation rests on the characteristic DIF pattern. [21][24]

*Follow-up targets after dermatitis herpetiformis diagnosis. [1][5]*

| Visit focus | Specific assessment | Action if abnormal |
| --- | --- | --- |
| Early treatment visits | Pruritus, lesion activity, GFD adherence, and dapsone adverse effects. [1] | Reinforce strict GFD, adjust symptomatic therapy within safety constraints, and evaluate toxicity. [1][12] |
| Nutritional and hematologic status | CBC, ferritin, folate, vitamin B12, calcium, and alkaline phosphatase. [5] | Identify impaired absorption or drug-related hematologic toxicity and direct further management. [5][12] |
| Associated disease screening | TSH/thyroid hormones, serum glucose, and AST/ALT. [5] | Evaluate detected autoimmune or hepatic abnormalities. [5] |
| Long-term stable disease | Annual review after dietary management is established. [5] | Continue surveillance and structured adherence assessment. [5] |

## References
1. Dermatitis herpetiformis - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/3000326
2. Dermatitis herpetiformis - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/3000326
3. Gluten-Free Diets and Dermatitis Herpetiformis | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/gluten-free-diets-dermatitis-herpetiformis-JD199502010000011
4. coeliac enteropathies in adults: the Paris consensus — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2022/07/01/gutjnl-2021-326645.full.pdf
5. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology | Gut — gut.bmj.com — https://gut.bmj.com/content/63/8/1210
6. LETTERS - Gut — gut.bmj.com — http://gut.bmj.com/cgi/reprint/53/10/1544
7. Transition from childhood to adulthood in coeliac disease - Gut — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2016/04/26/gutjnl-2016-311574.full.pdf
8. Dermatitis Herpetiformis: The Skin and the Gut - ACP Journals — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-93-6-857
9. Abstracts : Itch — journals.lww.com — https://journals.lww.com/itch/fulltext/2019/11001/abstracts.2.aspx
10. Dermatitis herpetiformis : Clinical & Experimental Dermatology — journals.lww.com — https://journals.lww.com/00003050-201910000-00003
11. Tetracyclines and niacinamide to the rescue in a case of dermatitis ... — journals.lww.com — https://journals.lww.com/iodd/fulltext/2022/08010/tetracyclines_and_niacinamide_to_the_rescue_in_a.9.aspx
12. Dermatitis Herpetiformis - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/dermatitis-herpetiformis
13. Dermatitis Herpetiformis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0300508921003564
14. Dapsone Induced Methemoglobinemia and Hemolysis... : Indian Journal of Dermatology — journals.lww.com — https://journals.lww.com/ijd/fulltext/2013/58050/dapsone_induced_methemoglobinemia_and_hemolysis_in.47.aspx
15. Details of the gluten-free diet for the patient with dermatitis herpetiformis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/0738081X9190033H
16. Dermatitis herpetiformis: Part II. Diagnosis, management, and prognosis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0190962210021213
17. Epidemiology, Presentation, and Diagnosis of Celiac Disease — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(20)35165-9/fulltext
18. Are We Ready for an Approved Therapy in Celiac Disease? — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(24)00167-7/pdf
19. Skin manifestations of celiac disease - Gastroenterology — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(05)00195-2/fulltext
20. Association of celiac disease and intestinal lymphomas and other ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(05)00196-4/fulltext
21. Dermatitis herpetiformis in an adolescent patient - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7007020
22. Improving the Diagnosis of Dermatitis Herpetiformis Using the Intraepithelial Lymphogram - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10819692
23. Granular IgA Deposits in the Skin of Patients with Coeliac Disease — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/29972219
24. The diagnosis and treatment of dermatitis herpetiformis - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4435051

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.